These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 19527095)

  • 1. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme.
    Uyl-de Groot CA; Stupp R; van der Bent M
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):235-41. PubMed ID: 19527095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
    Lamers LM; Stupp R; van den Bent MJ; Al MJ; Gorlia T; Wasserfallen JB; Mittmann N; Jin Seung S; Crott R; Uyl-de Groot CA;
    Cancer; 2008 Mar; 112(6):1337-44. PubMed ID: 18213621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death.
    Wasserfallen JB; Ostermann S; Pica A; Mirimanoff RO; Leyvraz S; Villemure JG; Stupp R
    Cancer; 2004 Nov; 101(9):2098-105. PubMed ID: 15389472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of glioblastoma: comparison of clinical practices and cost-effectiveness in two cohorts of patients (2008 versus 2004) diagnosed in a French university hospital.
    Diebold G; Ducray F; Henaine AM; Frappaz D; Guyotat J; Cartalat-Carel S; Breant V; Fouquet A; Aulagner G; Honnorat J; Armoiry X
    J Clin Pharm Ther; 2014 Dec; 39(6):642-8. PubMed ID: 25164371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
    Messali A; Hay JW; Villacorta R
    Neuro Oncol; 2013 Nov; 15(11):1532-42. PubMed ID: 23935155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
    Martikainen JA; Kivioja A; Hallinen T; Vihinen P
    Pharmacoeconomics; 2005; 23(8):803-15. PubMed ID: 16097842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a two-centre German cohort trial with systematic comparison and effect-to-treatment analysis.
    Roussakow SV
    BMJ Open; 2017 Nov; 7(11):e017387. PubMed ID: 29102988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
    Waschke A; Arefian H; Walter J; Hartmann M; Maschmann J; Kalff R
    J Neurooncol; 2018 Jun; 138(2):359-367. PubMed ID: 29468446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroup economic analysis for glioblastoma in a health resource-limited setting.
    Wu B; Miao Y; Bai Y; Ye M; Xu Y; Chen H; Shen J; Qiu Y
    PLoS One; 2012; 7(4):e34588. PubMed ID: 22511951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death.
    Wasserfallen JB; Ostermann S; Leyvraz S; Stupp R
    Neuro Oncol; 2005 Apr; 7(2):189-95. PubMed ID: 15831237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
    Hillner BE; Agarwala S; Middleton MR
    J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments.
    Messali A; Villacorta R; Hay JW
    Pharmacoeconomics; 2014 Dec; 32(12):1201-12. PubMed ID: 25085219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
    Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
    J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme.
    De Sanctis V; Mazzarella G; Osti MF; Valeriani M; Alfó M; Salvati M; Banelli E; Tombolini V; Enrici RM
    Anticancer Drugs; 2006 Sep; 17(8):969-75. PubMed ID: 16940807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The economics of temozolomide in brain cancer.
    Crott R
    Expert Opin Pharmacother; 2007 Aug; 8(12):1923-9. PubMed ID: 17696793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
    Mabasa VH; Taylor SC
    J Oncol Pharm Pract; 2006 Jun; 12(2):105-11. PubMed ID: 16984749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
    Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
    Xiang Y; Chen Y; Xu Z; Zhou S; Qin Z; Chen L; Xiao D; Liu S
    J Neurooncol; 2024 Jun; 168(2):259-267. PubMed ID: 38563851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.